Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ajp.20568 | DOI Listing |
NPJ Vaccines
December 2024
Comprehensive AIDS Research Center, Pandemic Research Alliance Unit, Center for Infection Biology, School of Basic Medical Sciences, Tsinghua University, 100084, Beijing, China.
DS-Cav1, SC-TM, and DS2 are distinct designer pre-fusion F proteins (pre-F) of respiratory syncytial virus (RSV) developed for vaccines. However, their immunogenicity has not been directly compared. In this study, we generated three recombinant vaccines using the chimpanzee adenovirus vector AdC68 to express DS-Cav1, SC-TM, and DS2.
View Article and Find Full Text PDFJ Clin Virol
December 2024
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Am J Primatol
December 2024
IPHC UMR 7178, CNRS, Université de Strasbourg, Strasbourg, France.
Nat Immunol
October 2024
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.
View Article and Find Full Text PDFSci Adv
August 2024
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
COVID-19 vaccines have successfully reduced severe disease and death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nonetheless, COVID-19 vaccines are variably effective in preventing transmission and symptomatic SARS-CoV-2 infection. Here, we evaluated the impact of mucosal or intramuscular vaccine immunization on airborne infection and transmission of SARS-CoV-2 in Syrian hamsters.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!